Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In a population of patients with venous thromboembolism and treated with oral anticoagulants (OAC) in routine clinical practice in Denmark this study will describe patients treated with each OAC
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| VKA patients | Vitamin K antagonist (VKA) patients |
| |
| NOAC patients | nonvitamin K antagonist oral anticoagulants (NOAC) patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-Interventional | Other | Non-Interventional |
|
| Measure | Description | Time Frame |
|---|---|---|
| Hospitalization rate in VKA patients for VTE | Hospitalization rate for first-time Venous thromboembolism (VTE) in Vitamin K antagonist (VKA) patients | Approximately 180 months |
| VTE hospitalization rate in VKA patients by sex | Approximately 180 months | |
| VTE hospitalization rate in VKA patients by age | Approximately 180 months | |
| Hospitalization rate in NOAC patients for VTE | Hospitalization rate for first-time venous thromboembolism in nonvitamin K antagonist oral anticoagulants (NOAC) patients | Approximately 180 months |
| VTE hospitalization rate in NOAC patients by sex | Approximately 180 months | |
| VTE hospitalization rate in NOAC patients by age | Approximately 180 months | |
| Duration of Treatment in NOAC patients | Approximately 180 months | |
| Duration of treatment in VKA patients | Approximately 180 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. In the analyses on type and duration of anticoagulant use, Patients with cancer will be excluded as they typically receive low molecular heparin directly from the hospital and their use of anticoagulants can therefore not be captured by redeemed prescriptions at pharmacies.
Not provided
Not provided
Not provided
The Danish National Patient Registry (DNPR), covering all Danish hospitals, will be used to identify first-time and recurrent VTE cases diagnosed from 01-Jan-2006 through 31-Dec-2015.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
Not provided
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D054556 | Venous Thromboembolism |
| ID | Term |
|---|---|
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided